The financials
Precigen, Inc. by the numbers
Precigen, Inc. (PGEN) reported revenue of $23M in Q1 2026 (quarter ended March 31, 2026), up 1634% from the same quarter a year earlier. That came with net loss of $7.9M. For the full year FY2025, revenue was $9.7M (+147% year on year) and net income −$251M. Its largest product in 2026-Q1 was Papzimeos at $22M, 93% of the disclosed total, just ahead of Service at 6.1%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $23M | $1.3M | +1634% |
| Operating income | −$6.0M | −$23M | n/a |
| Net income | −$7.9M | −$54M | n/a |
| Diluted EPS | −$0.02 | −$0.18 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Papzimeos | $22M | 93% |
| Service | $1.4M | 6.1% |
| Exemplar | $237K | 1.0% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $23.3M (+2368%)
Service grew +25% year on yearExemplar +17% year on year
Segment Latestquarter on quarteryear on year
- Papzimeos$21.6M$21.6MQoQ -year on year ---
- Service$1.4M$1.4MQoQ +51%year on year +25%+51%+25%
- Exemplar$237.0K$237.0KQoQ -year on year +17%-+17%
- Other--QoQ -year on year ---